 Shares of Reviva Pharmaceuticals Holdings Inc. soared 76.6 in trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a mid-stage clinical trial. Reviva said that the investigational therapy, brilaroxazine, met all safety endpoints and helped with social functioning and cognition in the randomized, placebo-controlled, double-blind Phase 2 clinical study. 